Oral small molecule GLP-1 receptor agonist
Aleniglipron 90 mg tablet once daily
ALENIG_PO_90MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -7.01 (-16.98 to 4.83) | 0.70 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -9.53 (-15.27 to -2.21) | 0.72 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -8.82 (-15.11 to -0.47) | 0.61 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.08 (0.00 to 1.03) | 0.91 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.31 (0.32 to 5.85) | 0.60 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.47 (2.31 to 9.07) | 0.38 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.37 (2.87 to 27.91) | 0.26 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.88 (0.86 to 4.24) | 0.51 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.23 (0.84 to 6.27) | 0.46 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.75 (0.54 to 17.24) | 0.43 |